An AI Predictive Model to Determine Who Benefits from ADT with Radiation: Working Smarter, Not Harder

Whether you are a surgical, medical, or radiation oncologist, the care goals remain the same, that is, achieving a durable treatment response. For patients with localized intermediate-risk prostate cancer undergoing radiation treatment, identifying those who would derive additional benefit from androgen deprivation therapy (ADT) is an ongoing challenge. To help physicians make this decision, prognostic risk scores have been derived from biobanked pathology specimens^1-3 coupled with well-annotated clinical and imaging data from multiple phase III trials.